Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7981 to 7995 of 8914 results

  1. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

    Withdrawn advice

  2. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Withdrawn advice

  3. Difficult-to-treat scabies: oral ivermectin (ESUOM29)

    November 2024: This evidence summary has been withdrawn because licensed products are now available.

    Withdrawn advice

  4. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Withdrawn advice

  5. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Withdrawn advice

  6. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Withdrawn advice

  7. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn advice

  8. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  9. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  10. Clostridium difficile infection: fidaxomicin (ESNM1)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  11. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Withdrawn advice

  12. Acute diarrhoea in adults: racecadotril (ESNM11)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  13. Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  14. Actinic keratosis: ingenol mebutate gel (ESNM14)

    This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.

    Withdrawn advice

  15. Schizophrenia: lurasidone (ESNM15)

    This evidence summary has been replaced by ESNM48

    Withdrawn advice